Johnson & Johnson $JNJ Shares Sold by CNB Bank

CNB Bank lessened its stake in Johnson & Johnson (NYSE:JNJ) by 5.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,629 shares of the company’s stock after selling 333 shares during the quarter. CNB Bank’s holdings in Johnson & Johnson were worth $860,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. GFG Capital LLC purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter worth about $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $52,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.1%

Shares of Johnson & Johnson stock opened at $190.38 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $194.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.76. The business’s fifty day moving average price is $182.26 and its two-hundred day moving average price is $166.13. The company has a market capitalization of $458.69 billion, a P/E ratio of 18.38, a PEG ratio of 2.26 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on JNJ shares. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday. UBS Group lifted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Finally, Stifel Nicolaus lifted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.